Fosun Pharma: The registration application for electrolyte powder medicine of its holding subsidiary, Fosun Polyethylene Glycol Electrolyte Complex, has been accepted.

Fosun Pharma announced that its holding subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for compound polyethylene glycol electrolyte powder accepted by the National Medical Products Administration. The drug is intended for use in the preparation of colonoscopy, barium enema X-ray contrast, and preoperative bowel preparation for colon and rectal surgery. As of May 2025, Fosun Pharma Group has invested approximately 4.74 million yuan in research and development for the series of compound polyethylene glycol electrolyte powder drugs, including this drug. In 2024, the sales revenue of compound polyethylene glycol electrolyte powder in China was approximately 307 million yuan.